These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 17706807

  • 1. Differences in management and outcome of ischemic and non-ischemic cardiomyopathy.
    Ng AC, Sindone AP, Wong HS, Freedman SB.
    Int J Cardiol; 2008 Sep 26; 129(2):198-204. PubMed ID: 17706807
    [Abstract] [Full Text] [Related]

  • 2. Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.
    Hamada M, Hara Y, Ohtsuka T, Suzuki J, Saeki H, Ogimoto A, Shigematsu Y.
    J Cardiovasc Pharmacol; 2003 Jan 26; 41 Suppl 1():S5-10. PubMed ID: 12688389
    [Abstract] [Full Text] [Related]

  • 3. Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Seghatol FF, Shah DJ, Diluzio S, Bello D, Johnson MR, Cotts WG, O'Donohue JA, Bonow RO, Gheorghiade M, Rigolin VH.
    Am J Cardiol; 2004 Apr 01; 93(7):854-9. PubMed ID: 15050488
    [Abstract] [Full Text] [Related]

  • 4. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.
    Castelli G, Fornaro A, Ciaccheri M, Dolara A, Troiani V, Tomberli B, Olivotto I, Gensini GF.
    Circ Heart Fail; 2013 Sep 01; 6(5):913-21. PubMed ID: 23888044
    [Abstract] [Full Text] [Related]

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 01; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 6. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A.
    J Cardiovasc Pharmacol; 2007 Nov 01; 50(5):585-9. PubMed ID: 18030070
    [Abstract] [Full Text] [Related]

  • 7. Metoprolol-induced functional benefit in dilated cardiomyopathy is sustained over four years and favorably influences outcome.
    De Maria R, Di Lenarda A, Gavazzi A, Porcu M, Sinagra G, Parolini M, SPIC (Italian Multicenter Cardiomyopathy Study) Group.
    Ital Heart J; 2001 Feb 01; 2(2):130-8. PubMed ID: 11256541
    [Abstract] [Full Text] [Related]

  • 8. Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in China.
    Liu X, Yu H, Pei J, Chu J, Pu J, Zhang S.
    Heart Lung Circ; 2014 Sep 01; 23(9):818-26. PubMed ID: 24881031
    [Abstract] [Full Text] [Related]

  • 9. Impact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy.
    Badenhorst D, Norton GR, Sliwa K, Brooksbank R, Essop R, Sareli P, Woodiwiss AJ.
    Pharmacogenomics J; 2007 Oct 01; 7(5):339-45. PubMed ID: 17117186
    [Abstract] [Full Text] [Related]

  • 10. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, Thebaut JF, Genoun M, French National College of Cardiologists.
    Arch Cardiovasc Dis; 2012 Oct 01; 105(6-7):355-65. PubMed ID: 22800720
    [Abstract] [Full Text] [Related]

  • 11. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy.
    Herrmann S, Schmidt-Petersen K, Pfeifer J, Perrot A, Bit-Avragim N, Eichhorn C, Dietz R, Kreutz R, Paul M, Osterziel KJ.
    Eur Heart J; 2001 Oct 01; 22(20):1948-53. PubMed ID: 11601839
    [Abstract] [Full Text] [Related]

  • 12. [How the natural history of dilated cardiomyopathy has changed. Review of the Registry of Myocardial Diseases of Trieste].
    Di Lenarda A, Pinamonti B, Mestroni L, Salvi A, Sabbadini G, Gregori D, Perkan A, Zecchin M, Carniel E, Bussani R, Silvestri F, Morgera T, Camerini F, Sinagra G.
    Ital Heart J Suppl; 2004 Apr 01; 5(4):253-66. PubMed ID: 15185463
    [Abstract] [Full Text] [Related]

  • 13. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
    Pölzl G, Gouya G, Hügel H, Frick M, Ulmer H, Pachinger O.
    Wien Klin Wochenschr; 2002 Oct 31; 114(19-20):833-9. PubMed ID: 12503474
    [Abstract] [Full Text] [Related]

  • 14. The prognostic value of renal dysfunction in patients with chronic heart failure: 12-month follow-up.
    Roik M, Starczewska MH, Stawicki S, Solarska-Półchłopek A, Warszawik O, Oreziak A, Kochanowski J, Kosior D, Opolski G.
    Kardiol Pol; 2006 Jul 31; 64(7):704-11; discussion 712. PubMed ID: 16886127
    [Abstract] [Full Text] [Related]

  • 15. Impact of gender on outcomes in chronic systolic heart failure.
    Ng AC, Wong HS, Yong AS, Sindone AP.
    Int J Cardiol; 2007 Apr 25; 117(2):214-21. PubMed ID: 17064798
    [Abstract] [Full Text] [Related]

  • 16. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators.
    J Am Coll Cardiol; 2009 Jun 09; 53(23):2150-8. PubMed ID: 19497441
    [Abstract] [Full Text] [Related]

  • 17. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.
    Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, Foley B, Bourge RC.
    J Heart Lung Transplant; 2005 Dec 09; 24(12):2196-201. PubMed ID: 16364871
    [Abstract] [Full Text] [Related]

  • 18. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
    Mariotti R, Borelli G, Coceani M, Zingaro S, Barison A, Morelli I, Rondinini L.
    J Clin Pharm Ther; 2008 Aug 09; 33(4):349-56. PubMed ID: 18613852
    [Abstract] [Full Text] [Related]

  • 19. The impact of left ventricular reconstruction on survival in patients with ischemic cardiomyopathy.
    O'Neill JO, Starling RC, McCarthy PM, Albert NM, Lytle BW, Navia J, Young JB, Smedira N.
    Eur J Cardiothorac Surg; 2006 Nov 09; 30(5):753-9. PubMed ID: 17023172
    [Abstract] [Full Text] [Related]

  • 20. Prognostic factors and predictors of in-hospital mortality of patients with heart failure with preserved left ventricular ejection fraction.
    Pérez de Isla L, Zamorano J, Hernández N, Contreras L, Rodrigo JL, Almería C, Aubele AL, Mataix L, Macaya C.
    J Cardiovasc Med (Hagerstown); 2008 Oct 09; 9(10):1011-5. PubMed ID: 18799963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.